BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • BCI
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Tuesday, July 7, 2026
Home » Topics » Science » Drug design, drug delivery and technologies

Drug design, drug delivery and technologies
Drug design, drug delivery and technologies RSS Feed RSS

Futuristic medicine research illustration with petri dishes and pipette
Drug Design, Drug Delivery & Technologies

Gandeeva and Moderna enter research collaboration using AI-enabled cryogenic electron microscopy

March 31, 2023
Gandeeva Therapeutics Inc. has entered into a research collaboration with Moderna Inc. to...
Read More
Scanning electron microscope image of cancer cells killed by programmed Photorhabdus virulence cassettes
Drug Design, Drug Delivery & Technologies

Molecular syringe could revolutionize therapeutic protein delivery

March 30, 2023
By Helen Albert
A research team based at MIT and Harvard has engineered a bacterial injection system to precisely deliver proteins to human cells. This work, published online March 29, 2023, in Nature, is important as while more and more molecular therapies are being developed, off-target effects are always a concern and precise targeting of cells and tissues can still be a challenge.
Read More
DNA, drug development concept art.
Drug Design, Drug Delivery & Technologies

Moderna and Generation Bio collaborate to develop nonviral genetic medicines

March 24, 2023
Moderna Inc. and Generation Bio Co. have entered into a strategic collaboration to combine Moderna’s biological and technical expertise...
Read More
Drug research
Drug Design, Drug Delivery & Technologies

Charm Therapeutics and Bristol Myers Squibb establish drug discovery collaboration

March 21, 2023
Charm Therapeutics Ltd. has entered into a strategic discovery collaboration with Bristol Myers Squibb Co. for the identification and optimization of compounds against Bristol Myers Squibb's selected targets.
Read More
3D concept image of nanoparticle layers
Immuno-oncology

Talem Therapeutics collaborates with Libera Bio to develop novel antibodies for use with MPN delivery

March 16, 2023
Talem Therapeutics LLC, an independently...
Read More
Concept art for RNA interference, gene silencing.
Neurology/Psychiatric

Switch Therapeutics launches with focus on conditionally activated siRNA molecules

March 14, 2023
Switch Therapeutics Inc. has announced its launch following US$52 million of financing. The company was founded on the premise of a new type of RNA medicine that integrates nucleic acid nanotechnology and RNA interference (RNAi) science.
Read More
DNA illustration
Drug Design, Drug Delivery & Technologies

Epic Bio achieves persistent gene activation using GEMS platform

March 14, 2023
Epic Bio (Epicrispr Biotechnologies Inc.) has presented new data demonstrating the achievement of persistent gene activation using its Gene Expression Modulation System (GEMS) platform.
Read More
Photomicrograph of bone marrow aspirate showing myeloblasts of acute myeloid leukemia
Cancer

A new dual strategy for acute myeloid leukemia

March 13, 2023
By Mar de Miguel
Two molecules that affected the cell cycle only of acute myeloid leukemia (AML) cells could be used as a clinical strategy against this pathology. Scientists at Memorial Sloan Kettering Cancer Center and Harvard University have discovered that DEG-35 and DEG-77 arrested the cell cycle and promoted cell differentiation and apoptosis in these cells.
Read More
Gene editing of human embryos
Genetic/Congenital

Standard method for evaluating germline edits has large blind spots

March 10, 2023
By Xavier Bofill Bruna
The intended use of gene editing tools on pre-implantation human embryos would be to avoid the development of congenital diseases in the upcoming baby. But it may have its own risks. Those risks were illustrated in a publication in the March 7, 2023, issue of Nature Communications, where researchers from the Center for Embryonic Cell and Gene Therapy, Oregon Health & Science University (OHSU) showed that the method that is most frequently used for evaluating the effects of gene editing zygotes did not always result in an accurate picture of those edits.
Read More
Drug Design, Drug Delivery & Technologies

Ampersand Biomedicines set to develop programmable, more targeted therapeutics

March 8, 2023
Flagship Pioneering Inc. has unveiled Ampersand Biomedicines, a company creating programmable medicines that are safer, more tolerable and effective by acting at the site of disease. Flagship has initially committed US$50 million to advance Ampersand's Address, Navigate, Design (AND) Platform and develop an initial pipeline of medicines across a range of disease areas.
Read More
Previous 1 2 … 47 48 49 50 51 52 53 54 55 … 416 417 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 6, 2026.
  • CINP 2026: Prenatal and adolescent stress shape brain vulnerability

    BioWorld Science
    Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
  • Ontrack Therapeutics divulges compounds for neurodegenerative diseases

    BioWorld Science
    Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
  • IPO puzzle pieces

    Neuracle eyes Shanghai IPO as global BCI funding surges

    BioWorld
    Neuracle Medical Technology Co. Ltd. is seeking a Shanghai IPO that could make it China’s first publicly listed invasive brain-computer interface (BCI) company,...
  • Modius Spero wearable neuromodulation device

    Neurovalens granted FDA approval for PTSD therapy for US veterans

    BioWorld
    Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing